Arena Capital Advisors’s Orion Biotech Opportunities Corp. Warrant ORIAW Stock Holding History

Arena Capital Advisors’s Portfolio ORIAW Stock Details ORIAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-111,314	Closed	-$8.89K	–	100
2023 Q1	$8.89K	Hold	111,314	–	–	0.01%	68
2022 Q4	$16.9K	Hold	111,314	–	–	0.01%	91
2022 Q3	$20K	Hold	111,314	–	–	0.01%	145
2022 Q2	$17K	Hold	111,314	–	–	﹤0.01%	197
2022 Q1	$41K	Sell	111,314 -8,686	-7%	-$4.48K	0.01%	221
2021 Q4	$115K	Hold	120,000	–	–	0.01%	263
2021 Q3	$105K	Buy	+120,000	New	+$156K	0.01%	288

Arena Capital Advisors's ORIAW Position: Q2 2023 in Review

Arena Capital Advisors sold out of Orion Biotech Opportunities Corp. Warrant (ORIAW) in Q2 2023, closing a stake of 111,314 shares — an estimated $8.89K sold.

Arena Capital Advisors first reported a position in ORIAW in Q3 2021 and held it in 7 quarters. The position peaked at $115K in Q4 2021. 0 funds tracked by Wall St. Rank hold ORIAW as of Q2 2023.

Arena Capital Advisors reported no remaining Orion Biotech Opportunities Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Arena Capital Advisors sold 111,314 Orion Biotech Opportunities Corp. Warrant shares in Q2 2023, an estimated $8.89K.
Arena Capital Advisors first reported a position in Orion Biotech Opportunities Corp. Warrant in Q3 2021 and held it in 7 quarters.
Arena Capital Advisors's Orion Biotech Opportunities Corp. Warrant position peaked at $115K in Q4 2021.
0 funds tracked by Wall St. Rank held Orion Biotech Opportunities Corp. Warrant as of Q2 2023.

Based on Arena Capital Advisors's 13F filing for Q2 2023, filed 1 Aug 2023.